SCHEMBL2366065

SCHEMBL2366065

CC[C@@H]1COC(=O)N1c1ccc(C(=O)N2CCN(c3ncc(C)cc3C)CC2)c(S(C)(=O)=O)c1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A9 P48067 5/20 0.39
SLC6A5 Q9Y345 1/20 0.39
P2RX3 P56373 3/20 0.38
P2RX2 Q9UBL9 3/20 0.38
LMNA P02545 2/20 0.35
TP53 P04637 1/20 0.35
MAPT P10636 1/20 0.35
NR1H2 P55055 4/20 0.35
KCNH2 Q12809 3/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NR1H3 Q13133 1/20 0.33
IDH1 O75874 1/20 0.33
SMO Q99835 1/20 0.33
NAAA Q02083 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2365931 0.94 SLC6A9 (0.39) SLC6A9SLC6A5P2RX3P2RX2LMNA
Hydrochloric Acid SCHEMBL2365764 0.93 SLC6A9 (0.37) SLC6A9SLC6A5P2RX3P2RX2LMNA
SCHEMBL2366514 0.92 SLC6A9 (0.39) SLC6A9SLC6A5LMNATP53MAPT
SCHEMBL2366281 0.90 SLC6A9 (0.40) SLC6A9SLC6A5LMNATP53MAPT
Hydrochloric Acid SCHEMBL2366801 0.89 P2RX3 (0.41) SLC6A9SLC6A5P2RX3P2RX2LMNA
Hydrochloric Acid SCHEMBL2366793 0.89 P2RX3 (0.41) SLC6A9SLC6A5P2RX3P2RX2LMNA
SCHEMBL2365855 0.89 IDH1 (0.40) SLC6A9SLC6A5P2RX3P2RX2LMNA
SCHEMBL2365861 0.89 IDH1 (0.40) SLC6A9SLC6A5P2RX3P2RX2LMNA
SCHEMBL2366041 0.87 SLC6A9 (0.42) SLC6A9SLC6A5P2RX3P2RX2NR1H2
SCHEMBL2366574 0.85 P2RX3 (0.44) P2RX3P2RX2LMNAMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2364975-B1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORP (JP) 2013-06-12 EP disclosed
US-8354401-B2 Oxazolidinone amide aromatic compounds for supressing MMP-9 production MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-01-15 US disclosed
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-10-27 US disclosed
EP-2364975-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2011-09-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110263571-A1 NOVEL AMIDE DERIVATIVE AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP2 SLC6A9 446/4885SLC6A5 2726/4885P2RX3 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.